Menu
Menu
Elysia Group, Ltd. was formed in 2013 to bridge the gaps between commercial, health economic, and market access teams by generating value spanning the interest of multiple stakeholders.
To solve issues, we take a rigorous academic approach while creating deliverables that are simple, easy to interpret, and focus on advancing the commercial strategy.
We have an agile, full-time team including PhD modelers and analysts to support day-to-day operations and projects. We also draw from a pool of leading experts in economics and clinical practice.
Bruce is a Co-Founder and Chief Executive Officer of Elysia Group. He brings deep expertise in modeling with a particular focus on economic models. Currently, he is also Affiliate Faculty at University of Washington.
Previously, Bruce led the HEOR group at Alliance Life Sciences where he was Vice President. He was also Visiting Senior Fellow at Taipei Medical University in Taiwan, Senior Fellow in the Pharmaceutical Outcomes Research & Policy Program at the University of Washington, and Economic Strategist at Goldman Sachs in New York.
Bruce holds a Ph.D. in Economics from the University of Washington and a B.A. from Columbia University in New York.
Louis Garrison, Ph.D., is an Emeritus Professor in the School of Pharmacy at the University of Washington. With a distinguished career in health economics and outcomes research, he has over 170 publications and has held leadership positions in both academia and industry. His research focuses on pharmaceutical policy, health technology assessment, and value-based healthcare. Dr. Garrison has been actively involved in ISPOR and advises various organizations on healthcare policy and economics. He holds a Ph.D. in Economics from Stanford University.
Jennifer King has over 20 years of experience in pricing and market access across oncology and orphan drugs. She has worked globally, advising clients on strategies to achieve optimal access for all stakeholders. Previously, she was Head of Pricing & Market Access at Celgene, where she successfully led reimbursement efforts in the Asia Pacific region and launched Abraxane globally. Jennifer holds a B.A. in Biochemistry from UC Berkeley and an MBA from Lehigh University.
Chao-Hsiun Tang, Ph.D., is a Professor at Taipei Medical University with expertise in health policy, health economics, and pharmacoepidemiology. Her research focuses on healthcare system performance, health technology assessment, and pharmaceutical policy. With numerous publications and contributions to national health policy, Prof. Tang has played a key role in shaping healthcare decision-making in Taiwan. She earned her Ph.D. in Public Health from the School of Hygiene and Public Health at Johns Hopkins University and has received several awards for her work.
© 2024 Elysia Group, LLC. All Rights Reserved.